Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
Bernd Kasper, Stefan Fruehauf, Bernd Schiedlmeier, Elisabeth Buchdunger, Anthony D. Ho, W. Jens ZellerVolume:
44
Language:
english
Pages:
6
DOI:
10.1007/s002800051001
Date:
September, 1999
File:
PDF, 170 KB
english, 1999